Efficacy comparison of immune treating strategies for NSCLC patients with negative PD-L1 expression

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
   PubMed Web of Science ®Google Scholar
• Bade BC, Dela Cruz CS. Lung Cancer 2020: epidemiology, Etiology, and Prevention. Clin Chest Med. 2020;41:1–24.
   PubMed Web of Science ®Google Scholar
• SEER Cancer Statistics Review, 1975-2018, Cancer Stat Facts: lung and Bronchus Cancer. Accessed 2021 Dec 29. https://seer.cancer.gov/statfacts/html/lungb.html.
   Google Scholar
• Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553:446–454.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Bauer TM, de Marinis F, et al. First-Line Lorlatinib or Crizotinib in Advanced -Positive Lung Cancer. N Engl J Med. 2020;383:2018–2029.
   PubMed Web of Science ®Google Scholar
• Wu Y-L, Tsuboi M, He J, et al. Osimertinib in resected-mutated non-small-cell lung cancer. N Engl J Med. 2020;383:1711–1723.
   PubMed Web of Science ®Google Scholar
• Yi M, Liao Z, Deng L, et al. High diagnostic value of miRNAs for NSCLC: quantitative analysis for both single and combined miRNAs in lung cancer. Ann Med. 2021;53:2178–2193.
   PubMed Web of Science ®Google Scholar
• Ding K, Yi M, Li L, et al. Interleukin polymorphisms and protein levels associated with lung cancer susceptibility and phenotypes. Expert Rev Clin Immunol. 2021;17:1029–1040.
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389:299–311.
   PubMed Web of Science ®Google Scholar
• Arbour KC, Riely GJ. Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review. JAMA. 2019;322:764–774.
   PubMed Web of Science ®Google Scholar
• Ettinger DS, Wood DE, Aggarwal C, et al. NCCN Guidelines Insights: non-Small Cell Lung Cancer, Version 1.2020. J Natl Compr Canc Netw. 2019;17:1464–1472.
   PubMed Web of Science ®Google Scholar
• Leonetti A, Wever B, Mazzaschi G, et al. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer. Drug Resist Updat. 2019;46:100644.
   PubMed Web of Science ®Google Scholar
• Doroshow DB, Sanmamed MF, Hastings K, et al. Immunotherapy in non-small cell lung cancer: facts and hopes. Clin Cancer Res. 2019;25:4592–4602.
   PubMed Web of Science ®Google Scholar
• Saenger Y, Magidson J, Liaw B, et al. Blood mRNA expression profiling predicts survival in patients treated with tremelimumab. Clin Cancer Res. 2014;20:3310–3318.
   PubMed Web of Science ®Google Scholar
• Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16:223–249.
   PubMed Web of Science ®Google Scholar
• Kazandjian D, Suzman DL, Blumenthal G, et al. FDA approval summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy. Oncologist. 2016;21:634–642.
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123–135.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627–1639.
   PubMed Web of Science ®Google Scholar
• Osmani L, Askin F, Gabrielson E, et al. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): moving from targeted therapy to immunotherapy. Semin Cancer Biol. 2018;52:103–109.
   PubMed Web of Science ®Google Scholar
• Huo X, Shen G, Liu Z, et al. Addition of immunotherapy to chemotherapy for metastatic triple-negative breast cancer: a systematic review and meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol. 2021;168:103530.
   PubMed Web of Science ®Google Scholar
• Gyawali B, Eisenhauer E, Tregear M, et al. Progression-free survival: it is time for a new name. Lancet Oncol. 2022;23:328–330.
   PubMedGoogle Scholar
• Liu Y, Yang T, Wei Y-W. What is the difference between overall survival, recurrence-free survival and time-to-recurrence? Br J Surg. 2020;107:e634.
   PubMedGoogle Scholar
• Dehbi H-M, Royston P, Hackshaw A. Life expectancy difference and life expectancy ratio: two measures of treatment effects in randomised trials with non-proportional hazards. Bmj. 2017;357:j2250.
   PubMedGoogle Scholar
• RoB 2: a revised Cochrane risk-of-bias tool for randomized trials. Accessed on 2021 Nov 28. https://methods.cochrane.org/bias/resources/rob-2-revised-cochrane-risk-bias-tool-randomized-trials
   Google Scholar
• Nishio M, Barlesi F, West H, et al. Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: results from the randomized phase 3 IMpower132 Trial. J Thorac Oncol. 2021;16:653–664.
   PubMed Web of Science ®Google Scholar
• Wang J, Lu S, Yu X, et al. Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2021;7:709–717.
   PubMed Web of Science ®Google Scholar
• Lu S, Wang J, Yu Y, et al. Tislelizumab plus chemotherapy as first-line treatment for locally advanced or metastatic nonsquamous NSCLC (RATIONALE 304): a randomized phase 3 trial. J Thorac Oncol. 2021;16:1512–1522.
   PubMed Web of Science ®Google Scholar
• Sugawara S, Lee JS, Kang JH, et al. Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer. Ann Oncol. 2021;32:1137–1147.
   PubMedGoogle Scholar
• Socinski MA, Nishio M, Jotte RM, et al. IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC. J Thorac Oncol. 2021;16:1909–1924.
   PubMed Web of Science ®Google Scholar
• Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288–2301.
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Cho BC, Reinmuth N, et al. Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non-small cell lung cancer: the MYSTIC phase 3 randomized clinical trial. JAMA Oncol. 2020;6:661–674.
   PubMed Web of Science ®Google Scholar
• Planchard D, Reinmuth N, Orlov S, et al. Arctic: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer. Ann Oncol. 2020;31:609–618.
   PubMed Web of Science ®Google Scholar
• Arrieta O, Barrón F, Ramírez-Tirado LA, et al. Efficacy and safety of pembrolizumab plus docetaxel vs docetaxel alone in patients with previously treated advanced non-small cell lung cancer: the PROLUNG phase 2 randomized clinical trial. JAMA Oncol. 2020;6:856–864.
   PubMed Web of Science ®Google Scholar
• Awad MM, Gadgeel SM, Borghaei H, et al. Long-Term Overall Survival From KEYNOTE-021 Cohort G: pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC. J Thorac Oncol. 2021;16:162–168.
   PubMed Web of Science ®Google Scholar
• Gadgeel S, Rodríguez-Abreu D, Speranza G, et al. Updated Analysis From KEYNOTE-189: pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2020;38:1505–1517.
   PubMed Web of Science ®Google Scholar
• Jotte R, Cappuzzo F, Vynnychenko I, et al. Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized phase iii trial. J Thorac Oncol. 2020;15:1351–1360.
   PubMed Web of Science ®Google Scholar
• Zhou C, Chen G, Huang Y, et al. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. Lancet Respir Med. 2021;9:305–314.
   PubMed Web of Science ®Google Scholar
• Yang Y, Wang Z, Fang J, et al. Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: a randomized, double-blind, phase 3 study (Oncology pRogram by InnovENT anti-PD-1-11). J Thorac Oncol. 2020;15:1636–1646.
   PubMed Web of Science ®Google Scholar
• Welsh J, Menon H, Chen D, et al. Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial. J Immunother Cancer. 2020;8:e001001.
   Google Scholar
• Theelen WSME, Peulen HMU, Lalezari F, et al. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial. JAMA Oncol. 2019;5:1276–1282.
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2019;381:2020–2031.
   PubMed Web of Science ®Google Scholar
• West H, McCleod M, Hussein M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:924–937.
   PubMed Web of Science ®Google Scholar
• Wu Y-L, Lu S, Cheng Y, et al. Nivolumab versus docetaxel in a predominantly chinese patient population with previously treated advanced NSCLC: checkMate 078 randomized phase iii clinical trial. J Thorac Oncol. 2019;14:867–875.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379:2040–2051.
   PubMed Web of Science ®Google Scholar
• Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389:255–265.
   PubMed Web of Science ®Google Scholar
• Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387:1837–1846.
   PubMed Web of Science ®Google Scholar
• Lacour M, Hiltbrunner S, Lee S-Y, et al. Adjuvant chemotherapy increases Programmed Death-Ligand 1 (PD-L1) expression in non-small cell lung cancer recurrence. Clin Lung Cancer. 2019;20:391–396.
   PubMed Web of Science ®Google Scholar
• Shin J, Chung J-H, Kim SH, et al. Effect of platinum-based chemotherapy on PD-L1 expression on tumor cells in non-small cell lung cancer. Cancer Res Treat. 2019;51:1086–1097.
   PubMedGoogle Scholar
• Fournel L, Wu Z, Stadler N, et al. Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer. Cancer Lett. 2019; 464. DOI:https://doi.org/10.1016/j.canlet.2018.11.023
   Google Scholar
• Coosemans A, Vankerckhoven A, Baert T, et al. Combining conventional therapy with immunotherapy: a risky business? Eur J Cancer. 2019;113:41–44.
   PubMedGoogle Scholar
• Curran MA, Montalvo W, Yagita H, et al. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A. 2010;107:4275–4280.
   PubMed Web of Science ®Google Scholar
• Duraiswamy J, Kaluza KM, Freeman GJ, et al. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res. 2013;73:3591–3603.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Ciuleanu T-E, Cobo M, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:198–211.
   PubMed Web of Science ®Google Scholar
• Lantuejoul S, Sound-Tsao M, Cooper WA, et al. PD-L1 testing for lung cancer in 2019: perspective from the IASLC Pathology Committee. J Thorac Oncol. 2020;15:499–519.
   PubMed Web of Science ®Google Scholar
• Paver EC, Cooper WA, Colebatch AJ, et al. Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation. Pathology. 2021;53:141–156.
   PubMed Web of Science ®Google Scholar
• Grote HJ, Feng Z, Schlichting M, et al. Programmed Death-Ligand 1 immunohistochemistry assay comparison studies in NSCLC: characterization of the 73-10 assay. J Thorac Oncol. 2020;15:1306–1316.
   PubMedGoogle Scholar
• Doroshow DB, Wei W, Gupta S, et al. Programmed Death-Ligand 1 tumor proportion score and overall survival from first-line pembrolizumab in patients with nonsquamous versus squamous NSCLC. J Thorac Oncol. 2021;16:2139–2143.
   PubMedGoogle Scholar
• Inomata M, Takata N, Mizushima I, et al. Immune checkpoint inhibitor for non-small cell lung cancer with negative or low tumor PD-L1 expression. Cancer Diagn Progn. 2021; 1: 173–177.
   PubMedGoogle Scholar
• Long J, Wang D, Yang X, et al. Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy. BMC Med. 2021;19:154.
   PubMedGoogle Scholar
• Samstein RM, Lee C-H, Shoushtari AN, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51:202–206.
   PubMed Web of Science ®Google Scholar
• Yamauchi T, Hoki T, Oba T, et al. T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors. Nat Commun. 2021;12:1402.
   PubMedGoogle Scholar
• Sun J, Zhang Z, Bao S, et al. Identification of tumor immune infiltration-associated lncRNAs for improving prognosis and immunotherapy response of patients with non-small cell lung cancer. J Immunother Cancer. 2020;8:e000110.
   Google Scholar
• Shi Y, Lei Y, Liu L, et al. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer. Cancer Med. 2021;10:2216–2231.
   PubMedGoogle Scholar
• Zhang J, Zhou N, Lin A, et al. ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer. Cancer Immunol Immunother. 2021;70:137–151.
   PubMed Web of Science ®Google Scholar